Solevo Greensburg opening December 20! More info

ALS and Medical Marijuana

In a recent study discussing the use of Cannabis by ALS sufferers, 10% of patients said that consuming cannabis provided moderate relief of several symptoms including appetite loss, depression, pain and managing excessive saliva. The study concludes that “there is a valid rationale to propose the use of cannabinoid compounds in the pharmacological management of ALS patients.”

Cannabis and ALS Progression

The Neural Regeneration Research journal has published a review detailing the latest findings in the use of cannabis-derived compounds to treat amyotrophic lateral sclerosis (ALS).

Cannabinoids, the bioactive compounds of Cannabis sativa, exert their activity by binding to the CB1 and CB2 receptors. The pathology of ALS is closely tied to the cannabinoid system. ALS patients’ spinal cord has been shown to present motor neuron damage triggered by immune system’s cells (microglia and macrophages) that express increased levels of the CB2 cannabinoid receptor.

“These data show how editing CB2-mediated processes could change ALS progression and how much the endocannabinoid system is potentially involved in reducing neuroinflammation, excitotoxicity and oxidative cell damage,” the review notes.

Cannabis and animal models of ALS

Previous studies have shown that cannabinoids have antioxidant, anti-inflammatory and neuroprotective actions in animal models of ALS. Cannabinoids seems to delay disease progression and prolong survival in these animals. However, only a few studies have investigated the effect of cannabinoids in human patients, which makes it difficult to interpret the results.

“According to a single observational study of patients with ALS, only the 10 percent who admitted consuming cannabis revealed moderate relief of several symptoms, including appetite loss, depression, pain and drooling,” researchers wrote. “In addition, spasticity is also a major problem for ALS patients, which reported that cannabis can subjectively improve spasticity.”

They added: “There is a valid rationale to propose the use of cannabinoid compounds in the pharmacological management of ALS patients. Cannabinoids indeed are able to delay ALS progression and prolong survival. However, most of the studies that investigated the neuroprotective potential of these compounds in ALS were performed in animal models, whereas the few clinical trials that investigated cannabinoids-based medicines were focused only on the alleviation of ALS-related symptoms, not on the control of disease progression.”
The researchers said they hope scientists will keep studying how cannabinoids may be of therapeutic use for ALS patients.

Links

Survey of cannabis use in patients with amyotrophic lateral sclerosis

American Journal of Hospice and Palliative Medicine®

Read more

Marijuana in the management of amyotrophic lateral sclerosis

American Journal of Hospice and Palliative Medicine®

Read more

Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Applications, and a Call for Clinical Trials

American Journal of Hospice and Palliative Medicine®

Read more

Join the Solevo Wellness Newsletter!

Sign up today and receive periodic updates about Solevo Wellness, medical marijuana in Pennsylvania, and upcoming educational events near you.

Your privacy is important to us. We will never share or sell your information.

 

©2018 Solevo Wellness